Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01517048 · ClinicalTrials.gov registry record

Brain-Derived Neurotrophic Factor in Obesity and Brain Function

A clinical trial, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
93
Enrollment target

NCT01517048: Completed study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

NCT01517048 is a clinical trial that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01517048 has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
93 participants
Enrollment target

Study Summary

Background: \- Prader-Willi syndrome (PWS) and MC4R genetic mutations are two conditions that can cause problems with appetite regulation. People with PWS often have behavior and thinking problems. People with MC4R mutations may have problems with attention. These problems may be related to Brain-Derived Neurotrophic Factor (BDNF), a protein that is important for brain development. Researchers want to study people with PWS and MC4R mutations to see how BDNF is involved in these conditions. Specifically, body weight and brain function will be studied, and compared with healthy volunteers. Objectives: \- To study how BDNF affects body weight and brain function in people with PWS and MC4R mutations. Eligibility: * Individuals of any age who have Prader-Willi syndrome or MC4R genetic mutations. * Healthy volunteers of any age to act as control participants. Design: * Participants will be screened with a medical history and physical exam. Height, weight, and waist/hip circumferences will be measured. Blood samples will be taken for genetic and other tests. * Participants will fill out questionnaires about eating habits, pain perception, and sleep behavior. * Participants will keep a 3-day food diary to record all food and drinks eaten. * Tests and questionnaires will be given to study thinking, speech, movement, behavior, and mood. Some tests will be done on a computer; other tests will be on paper. Tests may also involve performing tasks with blocks and other objects. * Participants may have other tests as directed. These will include hot and cold sensitivity tests, imaging studies like x-rays, and measurements of body fat and water content. * Treatment will not be provided as part of this study.

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2012-01-09
Est. Completion 2014-12-12

What the finished NCT01517048 record still lists

NCT01517048 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 93 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT01517048 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01517048 about?

NCT01517048 is a clinical study titled "Brain-Derived Neurotrophic Factor in Obesity and Brain Function". Background: \- Prader-Willi syndrome (PWS) and MC4R genetic mutations are two conditions that can cause problems with appetite regulation. People with PWS often have behavior and thinking problems. People with MC4R mutations may have problems with attention. These problems may be related to Brain-D...

What is the current status of trial NCT01517048?

This trial is currently completed. The enrollment target is 93 participants. The study started on 2012-01-09. Estimated completion is 2014-12-12.

Who is sponsoring clinical trial NCT01517048?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01517048, the US trial registry maintained by the National Library of Medicine. NCT01517048 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.